Illumina plans population-scale microarray test; Venter downplays likelihood of HLI contributing to the Precision Medicine Initiative;

> Illumina ($ILMN) shared details of its plans to gather data to support the creation of a population-scale microarray test. Article

> J. Craig Venter dismissed the proposition of Human Longevity, Inc. sharing data with the Precision Medicine Initiative as "unlikely." Piece

> OmniComm signed up a CRO for a 5-year deal covering its TrialMaster electronic data capture system. Release

> Genomics England added Australia's Garvan Institute of Medical Research to its list of collaborators. News

> Balaji Venkateswaran joined DNAnexus as chief technology officer. Item

> Eastern European drug discovery firm Selvita set up a bioinformatics-focused subsidiary. More

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.